THYROLAR-2
LOE ApproachingNDAORALTABLET
Approved
Nov 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
THYROLAR-2 is an oral tablet NDA approved in 1969 for thyroid hormone replacement therapy. The product treats hypothyroidism and related thyroid disorders through hormone supplementation. It serves patients requiring lifelong thyroid hormone management.
LOE Approaching
LOE-approaching product with low competitive pressure (30%) suggests a stable, mature franchise requiring lifecycle management and defensive commercial strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
THYROLAR-2 supports 1,423 linked career opportunities across commercial, operations, and legal functions. Working on this LOE-approaching product emphasizes supply chain resilience, competitive pricing strategy, and regulatory defense rather than launch or growth marketing.
DirectorSpecialty Representative
Worked on THYROLAR-2 at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.